Children's Hospital Zagreb
- Address
- lock Available on a paid plan
Therapeutics and Medical Devices
The department is advancing pediatric therapeutics by testing innovative medicines and diagnostic tools across several disease groups, aiming to improve safety and effectiveness for young patients.
- Evaluation of novel drug candidates for pediatric use
- Integration of advanced diagnostic equipment in clinical practice
- Development of personalized treatment algorithms
- Monitoring of long‑term safety in children
- Collaboration with research laboratories for biomarker discovery
Children’s Hospital Zagreb supports these efforts with a dedicated pediatric research team and state‑of‑the‑art facilities.
Digestive System Diseases
Studies focus on ulcerative colitis in children and adolescents, seeking therapies that induce remission and sustain disease control while minimizing side effects.
- Induction strategies for pediatric inflammatory bowel disease
- Maintenance regimens to prevent relapse
- Impact of treatment on growth and nutrition
- Quality‑of‑life assessments for young patients
- Long‑term outcome monitoring
The hospital’s gastroenterology unit collaborates closely with families to tailor care plans.
Hemic and Lymphatic Diseases
Research targets anemia associated with chronic kidney disease and childhood acute lymphoblastic leukemia, aiming to enhance treatment response and reduce treatment‑related complications.
- Therapeutic approaches to correct anemia in pediatric CKD
- Risk‑adapted chemotherapy protocols for ALL
- Integration of immunotherapy for B‑cell precursor leukemia
- Genetic and minimal residual disease profiling at diagnosis
- Strategies to lower induction‑phase mortality
By refining risk classification, the site strives to boost survival rates for young patients with blood‑related disorders.
Nervous System Diseases
The unit investigates pediatric multiple sclerosis and neurogenic detrusor overactivity, evaluating therapies that limit relapses and improve bladder function, respectively.
- Comparison of disease‑modifying agents for pediatric MS
- Assessment of relapse frequency and disability progression
- Non‑invasive management of bladder overactivity
- Safety monitoring of long‑term neurological treatments
- Functional outcome measures for children
Multidisciplinary teams combine neurology and urology expertise to deliver comprehensive care.
Pathological Conditions, Signs and Symptoms
A broader initiative addresses the identification and management of clinical signs across pediatric conditions, aiming to sharpen diagnostic accuracy and symptom relief.
- Standardized symptom assessment tools for children
- Early detection markers for emerging diseases
- Integration of patient‑reported outcomes into care pathways
- Holistic strategies to manage pain and fatigue
- Evaluation of health‑related quality of life metrics
The hospital emphasizes a child‑centered approach that balances medical intervention with overall wellbeing.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 11 of 14 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Alfasigma S.p.A.1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 60 other sites in Croatia
Therapeutic Area Benchmark — Croatia
Select a therapeutic area to compare against other sites in Croatia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Croatia
Market Share
Country: Croatia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Children's Hospital Zagreb
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Dose Finding Study Evaluating the Safety and Efficacy of Linaclotide in Pediatric Subjects 6 Months to Less Than 2 Years of Age with Functional Constipation (FC). | AbbVie Deutschland GmbH & Co. KG | Phase II | Not Recruiting | Dec 2023 | May 2025 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Epoetin Alfa | 1 | Unknown | 2023-12-21 | 2023-12-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.